Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05909800
Other study ID # PRIFEN-01
Secondary ID 2020-003916-28
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 29, 2022
Est. completion date July 2024

Study information

Verified date October 2023
Source Medical University of Warsaw
Contact Agnieszka Szypowska, MD, PhD,Prof
Phone +48223179426
Email agnieszka.szypowska@uckwum.pl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate of the effect of phenofibrate on the functions of beta cells in children with new diagnosis of type 1 diabetes. The main question it aims to answer is: whether phenofibrate may prolong residual beta-cell function therefore own insulin secretion. Participants will be asked to take a phenofibrate or identically appearing placebo (a neutral substance), orally, once daily, for 12 months with no knowledge what is administred to them. They will be invited for follow-up visits including blood tests every 3 months. Researchers will be monitoring the two groups for the safety of the phenofibrate, and at the trial end they compare the residual insulin secretion results in two groups.


Description:

Rationale: Preservation of residual pancreatic beta cell function in children with newly diagnosed T1D gives a chance for better diabetes control, reduction of chronic diabetes complications, and possibly temporary insulin withdrawal. Indication of a cheap drug for secondary prevention of T1D. Setting: Recruitment will be through the paediatric diabetes clinics at two participating centres in Warsaw, Poland (Department of Paediatrics, the Medical University of Warsaw and Department of Endocrinology and Diabetology, Children's Memorial Health Institute). The initiation of study treatment may be performed no later than 28 days after screening visit, and no later than in 8 weeks from diabetes diagnosis. PICO: Adolescent participants meeting inclusion criteria, newly diagnosed with type 1 diabetes will be randomly assigned to two groups, receiving either fenofibrate at a dose of 160 mg or placebo, and regularly assesed, every 3 months for the next year. Assuming increase by 50% of AUC of C-peptide in the test group compared to placebo, 88 subjects are needed to achieve power of 85%. If about 13% drop-out is assumed the total group size is 102 patients. Given randomization ratio 1:1, there is 51 patients in each group. Main study procedures: - Demographic and medical history. - Physical examination and vital signs: heart rate and blood pressure, respiration rate, body temperature. - Blood collection for laboratory analysis (hematology: morphology with automatic blood smear, biochemistry: ALT, AST, total bilirubin, albumin, amylase, lipase, total cholesterol, HDL, LDL, triglycerides, GGTP, HbA1c, TSH, FT4, Anti-Tg, Anti-TPO, CK, creatinine, urea, vitamin D, homocysteine, Anti-tTG IgA, IgA. - Urine pregnancy test (in girls with childbearing potential). - C-peptide and Glucose in MMTT stimulation assay. - Anti-insulin IAA antibodies, Antibodies to glutamic acid decarboxylase (GADA), Antibodies to tyrosine phosphatase (IA2A), Antibodies to the zinc transporter 8 (ZnT8). - IL1, IL2, IL10. - TNF alpha, IFN gamma. - Genetic study - WES genome sequencing, HLA DR3, DR4, DO8, DQ7. - FGM Libre Free Style Glucose Monitoring System. - Abdominal ultrasound. - Ultrasound of the thyroid gland. - Safety monitoring and AE collection. - IMP administration. Compliance will be assessed by collecting empty packages as well as by direct interview and participants receiving <75% of the recommended doses will be considered as non-compliant.


Recruitment information / eligibility

Status Recruiting
Enrollment 102
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 10 Years to 17 Years
Eligibility Inclusion Criteria: Subjects who meet all of the following criteria are eligible to participate in this study: 1. Subject or Legally accepted representative (LAR) able to understand and provide signed informed consent. Assent is also required of adolescents and children. - LAR of subjects = 17 years sign the "Information Leaflet and ICF for the Parent/Legal Guardian of Minor Subject". - Adolescents from 10-15 years sign "Children Assent form". - Adolescents from 16-17 years sign "Adolescent Assent form". 2. Age =10 and = 17 years. 3. Diagnosis of type 1 diabetes within 8 weeks before randomization (V0 visit) based on positive autoantibody (minimum 1 among: GADA, IA2A, ZnT4, IAA) and symptoms of type 1 diabetes according to the criteria of the Polish Diabetes Association (1 of the following): - symptoms of diabetes and blood glucose = 200 mg / dl (= 11.1 mmol/l), - when no symptoms or when diabetes symptoms are present and random glucose <200 mg/dl (<11.1 mmol/l) - then confirmation of the diagnosis is fasting blood glucose in 2 measurements = 126 mg/dl (= 7.0 mmol/l); each test must be performed on a different day, - in the absence of symptoms of hyperglycaemia and random glycaemia = 200 mg/dl (11.1 mmol/l), fasting glucose = 126 mg/dl (7.0 mmol/l) is a confirmation of the diagnosis, - if once or twice fasting blood glucose is 100-125 mg / dl (5.6-6.9 mmol/l), or if fasting blood glucose is below 100 mg/dl (5.6 mmol/l) ) exists, If there is a reasonable suspicion of impaired glucose tolerance or diabetes mellitus, an oral glucose tolerance test (OGTT) should be performed. At the 120th minute of the OGTT, blood glucose = 200 mg/dl (11.1 mmol/l) confirms the diagnosis of diabetes. 4. Male or nonpregnant and nonlactating female who is abstinent or agrees to use effective contraceptive methods throughout the course of the study. Acceptable birth control methods are the following: - Intrauterine device in place for at least 3 months. - Use of condom or diaphragm with spermicide for at least 14 days prior to the Visit 0 visit and through study completion. - Stable hormonal contraceptive for at least 2 months prior to the Visit 0 and continuing through study completion. 5. Females (menstruating) must have a negative urine beta-human chorionic gonadotropin hormone (hCG) pregnancy test at Visit 0. Exclusion Criteria: Subjects who meet any of the following criteria are not eligible to participate in this study: 1. Age under 10 or over 17. 2. Lack of consent of at least one the guardian LAR to participate in the study. 3. Treatment with any oral or injected anti-diabetic medications other than insulin. 4. The Subject or close Subject's family history, past or present of allergic or hypersensitivity reactions to fenofibrate or any of the excipients (including patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption). 5. Severe hypersensitivity reaction to any other drug. 6. Subjects with current or history of clinically significant renal impairment. 7. Subjects with current or history of clinically significant hepatic impairment. 8. Subjects with or history of significant gastrointestinal disease including celiac disease, gastroparesis, another disorder of intestinal absorption or motility. 9. Subject with current or history of gall bladder disease. 10. Present or history of chronic or acute pancreatitis, except acute pancreatitis due to severe hypertriglyceridaemia. 11. Photosensitivity or phototoxic reactions after the use of fibrates or chemically related substances, e.g. ketoprofen. 12. Subjects who tested positive for pregnancy at screening and V0 visit or who are currently breastfeeding. 13. Low blood albumin defined as clinically significant by investigator. 14. Patients with pre-disposing factors for myopathy and/or rhabdomyolysis, including personal and familial history of hereditary muscular disorders. Unexplained persistent elevated creatine phosphokinase levels considered clinically significant by the investigator. 15. The presence of circumstances that the Investigator considers problematic when obtaining informed consent or meeting the study guidelines, or that may invalidate the interpretation of test results or expose Subjects to unnecessary risk. 16. Inability or unwillingness to comply with study procedures. 17. Any medical condition or treatment the Investigator believes may expose the Subject to unnecessary risk during the study. 18. Participation in interventional or other drug research studies which could affect the objectives of this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Phenofibrate
Administred orally, once daily, for 12 months.
Placebo
Administred orally, once daily, for 12 months.

Locations

Country Name City State
Poland Clinical department of pediatric diabetology and paediatrics, DSK UCKWUM Warsaw Mazowieckie
Poland Diabetology Department, Children's Memorial Health Institute Warsaw Mazowieckie

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Warsaw Children's Memorial Health Institute, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in AUC in C-peptide stimulation test Assessment of pancreatic beta cell function by comparing the area under the curve (AUC) in the C-peptide stimulation test: Change in the mean insulin secretion measured on the basis of the C-peptide area under the curve in the stimulation test 12 months
Secondary Differences in C-peptide concentration in the stimulation test: change in the insulin secretion measured on the basis of the fasting C-peptide concentration Fasting C-peptide concentration in the stimulation test 0, 6, 12 months
Secondary Differences in parameters of diabetes control HbA1c 0,3,6,9,12 months
Secondary Daily insulin requirement Daily insulin requirement/kg of body mass 0,3,6,9,12 months
Secondary Interleukins IL1, IL2, IL10, TNF alpha, IFN gamma 0,6,12 months
Secondary Adverse Events occurence Safety will be evaluated through assessment of AEs, vital signs, physical examinations, USG findings, and laboratory evaluations. Any clinically significant laboratory occurring after study drug initiation must be reported by the investigator as an AE and/or SAE, as appropriate, and must be followed by additional laboratory evaluations until they return to normal range, stabilize, or until the change is no longer clinically relevant. All safety analyses will be conducted using the Safety Analysis Set. Adverse event data will be presented and tabulated according to MedDRA classification. 0,3,6,9,12 months
Secondary Differences in C-peptide concentration in the stimulation test: change in the insulin secretion measured on the basis of the fasting C-peptide concentration Maximum C-peptide concentration 0,6,12 months
Secondary Diabetes control and glucose fluctuations Mean blood glucose with standard deviation 0,3,6,9,12 months
Secondary Differences in glucose fluctuations Glucose variability index (CV%) 0,3,6,9,12 months
Secondary Parameter of glucose fluctuations Time in range 70-180mg/dl 0,3,6,9,12 months
Secondary Difference in autoantibodies Difference in anti-insulin IAA antibodies, antibodies against glutamic acid decarboxylase (GADA), antibodies to tyrosine phosphatase (IA2A), anti-zinc transporter antibodies 8 determination. 0,6,12 month
Secondary Genetical analysis WES Whole Exome Sequencing and HLA 1 per study
See also
  Status Clinical Trial Phase
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT03605329 - Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Recruiting NCT06050642 - Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop. N/A
Completed NCT05107544 - Metabolic, Physical Fitness and Mental Health Effects of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes N/A
Active, not recruiting NCT04443153 - Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes N/A
Completed NCT04569994 - A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes Phase 1
Completed NCT04521634 - Glycaemic Variability in Acute Stroke
Completed NCT04089462 - Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study N/A
Completed NCT03143816 - Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study Phase 4
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Completed NCT04042207 - Diabeloop for Highly Unstable Type 1 Diabetes N/A
Not yet recruiting NCT06068205 - COMPARATIVE ANALYSIS OF THE MORPHO-MECHANICAL PROPERTIES OF RED BLOOD CELLS EXTRACTED FROM DIABETIC PATIENTS WITH AND WITHOUT MICROVASCULAR COMPLICATIONS
Active, not recruiting NCT04974528 - Afrezza® INHALE-1 Study in Pediatrics Phase 3
Completed NCT04530292 - Home Intervention and Social Precariousness in Childhood Diabetes N/A
Completed NCT05428943 - OPT101 in Type 1 Diabetes Patients Phase 1
Recruiting NCT03988764 - Monogenic Diabetes Misdiagnosed as Type 1
Completed NCT05597605 - The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects N/A
Not yet recruiting NCT06422494 - The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II N/A